Comments and Abstracts from the 2012 EULAR Meeting in Berlin

Comments and Abstracts from the 2012 EULAR Meeting in Berlin. Somehow this is an inventory of blogposts:


Biosimilars
Celltrion will most probably launch an infliximab biosimilar in 2013. http://rheumatologe.blogspot.de/2012/06/biosimilars.html


Ustekinumab
Ustekinumab and other options in psoriatic arthritis. http://rheumatologe.blogspot.de/2012/07/ustekinumab-and-other-options-in.html  


Anti-CD-20 Monoclonal Antibody (like Rituximab)
Ofatumumab and ocrelizumab? have been analyzed in:
[AB0572] META-ANALYSIS OF THE KEY RHEUMATOID ARTHRITIS (RA) DISEASE ACTIVITY ENDPOINTS IN PATIENTS TREATED WITH B-CELL DEPLETING THERAPIES
S. Menon, K. Barker, E. Peeva, I. Gourley, A. Heatherington. Research and Development, Pfizer Inc, Cambridge, United States
http://rheumatologe.blogspot.de/2012/06/anti-cd-20-monoclonal-antibody.html 


Co-Stimulation-Inhibition
Subcutaneous abatacept, when will it be available?
I have an idea about this, but up to now couldn’t confirm the date.


Tocilizumab
In a head to head study tocilizumab monotherapy has been studied against humira monotherapy. http://rheumatologe.blogspot.de/2012/06/tocilizumab-monotherapy-vs-humira.html  
Concerning Tocilizumab, my most important question to solve at the EULAR 2012 has been: How about subcutaneous tocilizumab? http://rheumatologe.blogspot.de/2012/06/tocilizumab-at-eular-2012.html  


Sarilumab
Sarilumab, another anti-IL-6 monoclonal antibody, has already been in a phase 2 study last year, what’s new? http://rheumatologe.blogspot.de/2012/06/sarilumab-news-from-eular-2012.html

Sirukumab
Sirukumab (formerly known as CNTO 136) is a human MAB that binds to the cytokine IL-6
http://rheumatologe.blogspot.de/2012/07/sirukumab-at-eular-2012.htmlAtacicept
Has atacicept [works on BLys(B-lymphocyte stimulator) and APRIL (A PRoliferation Inducing Ligand)] shown new efficacy? http://rheumatologe.blogspot.de/2012/06/atacicept.html  


Pateclizumab
Pateclizumab is an anti-Lymphotoxin-alpha Monoclonal Antibody. http://rheumatologe.blogspot.de/2012/06/pateclizumab-anti-lymphotoxin-alpha.html


Secukinumab
Secukinumab (an Anti-Il17a Monoclonal Antibody). http://rheumatologe.blogspot.de/2012/06/secukinumab-anti-il17a-monoclonal.html


Small molecules / protein kinase inhibitors
Safety of different small molecules / protein kinase inhibitors
http://rheumatologe.blogspot.de/2012/06/safety-of-different-small-molecules.html


Tofacitinib
The oral jak inhibitor tofacitinib (CP-690,550) has attracted most attention. http://rheumatologe.blogspot.de/2012/07/tofacitinib-oral-jak-inhibitor-at-eular.html  


Fostamatinib
Concerning fostamatinib (a SYK inhibitor), how far have we come during the past year? http://rheumatologe.blogspot.de/2012/07/fostamatinib-at-eular-2012.html  

VX-509
VX-509, a JAK 3 directed small molecule
http://rheumatologe.blogspot.de/2012/07/vx-509-and-eular-2012.htmlAnakinra - IL-1Ra-Receptor antagonist
Anakinra and Pseudogout (calcium pyrophosphate crystal arthritis) at the EULAR 2012
http://rheumatologe.blogspot.de/2012/07/anakinra-and-pseudogout-calcium.html


SBI-087
SBI-087 is a SMIP (= small molecule immune pharmaceutical) binding to CD-20 http://rheumatologe.blogspot.de/2012/07/sbi-087-at-eular-2012.html

Mavrilimumab
Mavrilimumab is a human MAB for the treatment of rheumatoid arthritis. It targets the GMCSF receptor and alpha-chain. http://rheumatologe.blogspot.de/2012/07/mavrilimumab-at-eular-2012.html  


NKG2a
NNC141-0100 is a humanized anti-human NKG2A monoclonal antibody that blocks interaction between CD94/NKG2A.
http://rheumatologe.blogspot.com/2012/07/nkg2a-nnc141-0100-at-eular-2012.html
Cetrorelix
Cetrorelix is a gonadotropin-releasing hormone antagonist (GnRH antagonist). http://rheumatologe.blogspot.de/2012/07/cetrorelix-at-eular-2012.html  


CCX354-C
CCX354-C did better than expected. http://rheumatologe.blogspot.de/2012/07/ccx-354-c-at-eular-2012.html  


Dekavil
Dekavil - fibronectin-A-chain connected to IL-10
http://rheumatologe.blogspot.de/2012/07/dekavil-at-eular-2012.html


Baricitinib
Baricitinib (also known as INCB28050, LY3009104) is an oral JAK1 and JAK2 inhibitor.
http://rheumatologe.blogspot.de/2012/06/baricitinib-ly3009104-at-eular-2012-in.html


Iguratimod
Iguratimod is new DMARD is under way from Japan:
http://rheumatologe.blogspot.de/2012/06/iguratimod-at-eular-2012.html


Modified release prednisolone
On modified release prednisolone: http://rheumatologe.blogspot.de/2012/06/modified-release-prednisone.html  


Synavive
Synavive, a combination of 2 mgs of prednisolone and 200 mgs of dipyramidole
http://rheumatologe.blogspot.de/2012/07/synavive-crx-102-at-eular-2012.html


Acronyms of studies in rheumatology:
http://rheumatologe.blogspot.de/2012/06/acronyms-of-studies-in-rheumatoid.html


Tabalumab
Tabalumab is an anti-BAFF Monoclonal Antibody. http://rheumatologe.blogspot.de/2012/06/tabalumab-ly2127399-anti-baff.html

Rheumatoid Arthritis
Persistant Synovitis of Rheumatoid Arthritis in Remission http://rheumatologe.blogspot.de/2012/07/persistant-synovitis-of-rheumatoid.htmlAnkylosing Spondylitis
Ankylosing Spondylitis Refractory to TNF-inhibition in the light of EULAR 2012. http://rheumatologe.blogspot.de/2012/07/ankylosing-spondylitis-refractory-to.html  


Psoriatic Arthritis
Non-anti-TNF Biologics in Psoriatic Arthritis at EULAR 2011. http://rheumatologe.blogspot.de/2012/07/non-anti-tnf-biologics-in-psoriatic.html  

Gout and other crystal diseases
Gout and other crystal diseases / Canakinumab.
http://rheumatologe.blogspot.de/2012/07/gout-and-other-crystal-diseases-at.html


Fibromyalgia
Fibromyalgia and the influence of weather on symptoms. http://rheumatologe.blogspot.de/2012/06/fibromyalgia-and-influence-of-weather.html
Chronic Widespread Pain – a study presented at the EULAR 2012. http://rheumatologe.blogspot.de/2012/07/chronic-widespread-pain-study-presented.html  

Osteoarthritis
Strontium ranelate in Knee Osteoarthritis at the EULAR 2012
http://rheumatologe.blogspot.de/2012/07/strontium-ranelate-in-knee.html

CD-40
This is a very speculative subject, but who knows, maybe we're going to target CD-40 to treat rheumatoid arhtiris:
http://rheumatologe.blogspot.de/2012/08/targeting-cd-40-preliminaries-at-eular.html